A Diagnostic Conundrum in a Newly Diagnosed Ulcerative Colitis Patient Who Presented with Pleuropericardial Effusion

Document Type : Case Report

Authors

1 1Department of Gastroenterology, Sultan Abdulhamid Han Training and Research Hospital, Health Sciences University, Istanbul, Turkey

2 Department of Internal Medicine, Sultan Abdulhamid Han Training and Research Hospital, Health Sciences University, Istanbul, Turkey

3 Department of Gastroenterology, Sultan Abdulhamid Han Training and Research Hospital, Health Sciences University, Istanbul, Turkey

Abstract

Ulcerative colitis is a chronic inflammatory disease affecting mainly the colon and presenting with diarrhea, bloody defecation and
abdominal pain. Although cardiac and/or pulmonary involvement has been reported in patients with ulcerative colitis, it rarely
involves both the pleura and pericardium at the same time. Also, it is difficult to determine whether pulmonary or cardiac disease
is secondary to the ulcerative colitis drugs or to the underlying disease process. Here we present a rare case of pleuropericardial
effusion in a patient newly diagnosed with ulcerative colitis. In ulcerative colitis, the simultaneous involvement of the respiratory
and cardiovascular systems is uncommon yet potentially dangerous.

Keywords

References

1. Gisbert JP, Chaparro M. Acute severe ulcerative colitis: State of the art treatment. Best Pract Res Clin Gastroenterol. 2018;32-33:59–69. doi: 10.1016/j.bpg.2018.05.007. [PubMed: 30060940].
2. Beyazit Y, Sayilir A, Tanoglu A, Kekilli M, Kocak E, Ekiz F, et al. Plasma thrombin-activatable fibrinolysis inhibitor levels correlate with the disease activity of ulcerative colitis. Intern Med. 2016;55(14):1831–6. doi: 10.2169/internalmedicine.55.6473. [PubMed: 27432089].
3. Kekilli M, Tanoglu A. Inflammatory bowel disease is frequently encountered in Turkey and Iran but Less than North and West Europe. Ann Colorectal Res. 2013;1(3):111. doi: 10.17795/acr-14460.
4. Abu-Hijleh M, Evans S, Aswad B. Pleuropericarditis in a patient with inflammatory bowel disease: A case presentation and review of the literature. Lung. 2010;188(6):505–10. doi: 10.1007/s00408-010-9259-y.
5. Tozzi A, Biagini MR, Rastelli C, Galli A, Baldi D, Milani S. Mesalamineinduced pleuritis in a patient with ulcerative colitis. Inflamm Bowel Dis. 2009;15(1):158–9. doi: 10.1002/ibd.20533. [PubMed: 18629902].
6. Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2003;9(2):104–15. doi: 10.1097/00054725-200303000-00004. [PubMed: 12769444].
7. Moles KW, Varghese G, Hayes JR. Pulmonary involvement in ulcerative colitis. Br J Dis Chest. 1988;82:79–83. doi: 10.1016/0007-0971(88)90012-5.
8. Patwardhan RV, Heilpern RJ, Brewster AC, Darrah JJ. Pleuropericarditis: An extraintestinal complication of inflammatory bowel disease. Report of three cases and review of literature. Arch Intern Med. 1983;143(1):94–6. [PubMed: 6849612].
9. Basseri B, Enayati P, Marchevsky A, Papadakis KA. Pulmonary manifestations of inflammatory bowel disease: Case presentations and review. J Crohns Colitis. 2010;4(4):390–7. doi: 10.1016/j.crohns.2010.03.008. [PubMed: 21122534].
10. Oxentenko AS, Loftus EV, Oh JK, Danielson GK, Mangan TF. Constrictive pericarditis in chronic ulcerative colitis. J Clin Gastroenterol. 2002;34(3):247–51. [PubMed: 11873106].
11. Foster RA, Zander DS, Mergo PJ, Valentine JF. Mesalamine-related lung disease: Clinical, radiographic, and pathologic manifestations. Inflamm Bowel Dis. 2003;9(5):308–15. doi: 10.1097/00054725-200309000- 00004. [PubMed: 14555914].
12. Morelock SY, Sahn SA. Drugs and the pleura. Chest. 1999;116(1):212–21. doi: 10.1378/chest.116.1.212. [PubMed: 10424528].
13. Qanneta R, Garcia Pardo G, Florit Serra L. Acute pleuropericarditis in a patient with primary Sjogren’s syndrome and quiescent ulcerative colitis in longstanding 5-aminosalicylic acid therapy. J Crohns Colitis. 2013;7(10):e506–7. doi: 10.1016/j.crohns.2013.05.008. [PubMed: 23768863].
14. Calafat M, Manosa M, Cabre E, Domenech E. [Acute pericarditis associated with oral or topical mesalazine therapy in patients with ulcerative colitis]. Gastroenterol Hepatol. 2014;37(4):254–5. Spanish. doi: 10.1016/j.gastrohep.2013.09.004. [PubMed: 24333139].
15. Ji XQ, Wang LX, Lu DG. Pulmonary manifestations of inflammatory bowel disease. World J Gastroenterol. 2014;20(37):13501–11. doi: 10.3748/wjg.v20.i37.13501. [PubMed: 25309080]. [PubMed Central: PMC4188901].
16. Desai D, Patil S, Udwadia Z, Maheshwari S, Abraham P, Joshi A. Pulmonary manifestations in inflammatory bowel disease: A prospective study. Indian J Gastroenterol. 2011;30(5):225–8. doi: 10.1007/s12664- 011-0129-1. [PubMed: 21935713].
17. Bunu DM, Timofte CE, Ciocoiu M, Floria M, Tarniceriu CC, Barboi OB, et al. Cardiovascular manifestations of inflammatory bowel disease: Pathogenesis, diagnosis, and preventive strategies. Gastroenterol Res Pract. 2019;2019:3012509. doi: 10.1155/2019/3012509. [PubMed: 30733802]. [PubMed Central: PMC6348818].
18. Mitchell NE, Harrison N, Junga Z, Singla M. Heart under attack: Cardiac manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(11):2322–6. doi: 10.1093/ibd/izy157. [PubMed: 29788235].
19. Park EH, Kim BJ, Huh JK, Jeong EH, Lee SH, Bang KB, et al. Recurrent mesalazine-induced myopericarditis in a patient with ulcerative colitis. J Cardiovasc Ultrasound. 2012;20(3):154–6. doi: 10.4250/jcu.2012.20.3.154. [PubMed: 23185660]. [PubMed Central: PMC3498314].
20. Blum A, Shalabi R, Brofman T, Shajrawi I. Cardiac manifestations of ulcerative colitis. Isr Med Assoc J. 2009;11(12):764–5.
21. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12(30):4819–31. doi: 10.3748/wjg.v12.i30.4819. [PubMed: 16937463]. [PubMed Central: PMC4087615]
Iranian Journal of Colorectal Research
Volume 7, Issue 2
June 2019
Pages 1-4

Files

Share

How to cite

Statistics